GlassScriptPhysician profile
William J Sellers
NPI 1437411428
$14,072.57
in general payments reported to CMS, 2019-2025
18 companies · $2,163 in 2025
The $2,163 reported for 2025 was more than what 83% of Surgery providers received nationally (typical 2025 total: $281).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,412 · 2020: $29.12 · 2021: $306 · 2022: $3,047 · 2023: $5,048 · 2024: $1,067 · 2025: $2,163.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $4,000 · Food and Beverage: $3,513 · Travel and Lodging: $765.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $4,000.00 |
| Food and Beverage | $3,513.33 |
| Travel and Lodging | $764.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $11,586.03 | 2019-2025 | Da Vinci Surgical System |
| Thd America, INC. | $727.48 | 2023-2025 | |
| Medtronic, INC. | $429.40 | 2024-2025 | Interstim |
| Integra Lifesciences Corporation | $263.31 | 2022-2025 | Integra, Integra Dermal Regeneration Template, Omnigraft |
| Novo Nordisk INC | $250.00 | 2024-2025 | Wegovy |
| Innocoll Pharmaceuticals Limited | $212.04 | 2021-2022 | |
| Smith+Nephew, INC. | $167.10 | 2020-2023 | Collagenase Santyl, Iodosorb Ointment 40g USA, Acticoat 4" X 4" |
| Enterra Medical, INC. | $116.91 | 2024 | |
| Olympus America INC. | $97.72 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $48.41 | 2021-2022 | |
| Kerecis Limited | $40.37 | 2023 | Kerecis Omega3 Surgiclose, Kerecis Omega3 Graftguide, Kerecis Omega3 Marigen |
| Tela Bio, INC. | $28.57 | 2021 | |
| Heron Therapeutics, INC. | $20.22 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.01 | 2025 | Jardiance |
| Merck Sharp & Dohme LLC | $18.48 | 2023 | Verquvo, Belsomra |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bioventus LLC | $18.04 | 2023 | Theragenesis Bilayer Wound Matrix |
| Molnlycke Health Care US, LLC | $17.09 | 2023 | Melgisorb Ag, Mepilex Border Ag, Mepilex Border Flex |
| Boston Scientific Corporation | $12.39 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Sellers listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.